155 related articles for article (PubMed ID: 35799423)
1. Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.
Greiner J; Goetz M; Schuler PJ; Bulach C; Hofmann S; Schrezenmeier H; Dӧhner H; Schneider V; Guinn BA
Br J Haematol; 2022 Sep; 198(5):866-874. PubMed ID: 35799423
[TBL] [Abstract][Full Text] [Related]
2. Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.
Greiner J; Götz M; Hofmann S; Schrezenmeier H; Wiesneth M; Bullinger L; Döhner H; Schneider V
Cancer Immunol Immunother; 2020 Apr; 69(4):629-640. PubMed ID: 32020256
[TBL] [Abstract][Full Text] [Related]
3. A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.
Guinn BA; Schuler PJ; Schrezenmeier H; Hofmann S; Weiss J; Bulach C; Götz M; Greiner J
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298237
[TBL] [Abstract][Full Text] [Related]
4. Tumour-derived small extracellular vesicles suppress CD8+ T cell immune function by inhibiting SLC6A8-mediated creatine import in NPM1-mutated acute myeloid leukaemia.
Peng M; Ren J; Jing Y; Jiang X; Xiao Q; Huang J; Tao Y; Lei L; Wang X; Yang Z; Yang Z; Zhan Q; Lin C; Jin G; Zhang X; Zhang L
J Extracell Vesicles; 2021 Nov; 10(13):e12168. PubMed ID: 34807526
[TBL] [Abstract][Full Text] [Related]
5. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.
Shi Y; Xue Y; Wang C; Yu L
Hematology; 2022 Dec; 27(1):609-619. PubMed ID: 35621728
[TBL] [Abstract][Full Text] [Related]
6. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.
Greiner J; Ono Y; Hofmann S; Schmitt A; Mehring E; Götz M; Guillaume P; Döhner K; Mytilineos J; Döhner H; Schmitt M
Blood; 2012 Aug; 120(6):1282-9. PubMed ID: 22592607
[TBL] [Abstract][Full Text] [Related]
7. Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.
Forghieri F; Riva G; Lagreca I; Barozzi P; Bettelli F; Paolini A; Nasillo V; Lusenti B; Pioli V; Giusti D; Gilioli A; Colasante C; Galassi L; Catellani H; Donatelli F; Talami A; Maffei R; Martinelli S; Potenza L; Marasca R; Tagliafico E; Manfredini R; Trenti T; Comoli P; Luppi M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502069
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field.
Falini B; Sciabolacci S; Falini L; Brunetti L; Martelli MP
Leukemia; 2021 Nov; 35(11):3113-3126. PubMed ID: 33879827
[TBL] [Abstract][Full Text] [Related]
9. The effect of small molecule inhibitor NSC348884 on nucleophosmin 1-mutated acute myeloid leukemia cells.
Zhu JF; Han LL; Ma Y; Wang YX; Zhang F
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9145-9151. PubMed ID: 37843328
[TBL] [Abstract][Full Text] [Related]
10. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
11. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia.
Dong H; Ham JD; Hu G; Xie G; Vergara J; Liang Y; Ali A; Tarannum M; Donner H; Baginska J; Abdulhamid Y; Dinh K; Soiffer RJ; Ritz J; Glimcher LH; Chen J; Romee R
Proc Natl Acad Sci U S A; 2022 Jun; 119(25):e2122379119. PubMed ID: 35696582
[TBL] [Abstract][Full Text] [Related]
12. Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (
Chin L; Wong CYG; Gill H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834572
[TBL] [Abstract][Full Text] [Related]
13. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.
Du Pisani LA; Shires K
Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):106-14. PubMed ID: 26183674
[TBL] [Abstract][Full Text] [Related]
14. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML.
von Palffy S; Thorsson H; Peña-Martínez P; Puente-Moncada N; Sandén C; Blom AM; Henningsson R; Juliusson G; King B; Landberg N; Lazarevic V; Orsmark-Pietras C; Rissler M; Rissler V; Ågerstam H; Järås M; Lilljebjörn H; Fioretos T
Blood Adv; 2023 Apr; 7(7):1204-1218. PubMed ID: 36383712
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1
De Cicco M; Lagreca I; Basso S; Barozzi P; Muscianisi S; Bianco A; Riva G; Di Vincenzo S; Pulvirenti C; Sapuppo D; Siciliano M; Rosti V; Candoni A; Zecca M; Forghieri F; Luppi M; Comoli P
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345068
[TBL] [Abstract][Full Text] [Related]
16. NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
Zhao D; Zarif M; Eladl E; Capo-Chichi JM; Smith AC; Atenafu EG; Tierens A; Minden MD; Schuh A; Chang H
Leuk Res; 2022 Jul; 118():106869. PubMed ID: 35636054
[TBL] [Abstract][Full Text] [Related]
17. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
[TBL] [Abstract][Full Text] [Related]
18. PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation.
Liu J; Qin W; Wang B; Wang Z; Hua H; Zhou F; Jia Z; Wu P; Chao H; Lu X
Leuk Res; 2022 Jul; 118():106859. PubMed ID: 35617714
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
[TBL] [Abstract][Full Text] [Related]
20. Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia.
Bailey GD; Doolan L; Baskar A; Smith LC; Seedhouse CH
Sci Rep; 2020 Oct; 10(1):17695. PubMed ID: 33077765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
